131 Elisa Neuvonen: The role of psychosocial factors in dementia prevention : from observational studies to a multidomain prevention trial


130 Juha Onatsu: Inflammatory, neuroaxonal  and imaging biomarkers in acute ischemic stroke


129 Antti Cajanus: Diagnostic brain imaging and blood biomarkers for early frontotemporal lobar degeneration

128 Anna Rosenberg: Dementia prevention in at-risk individuals: Focus on selection and engagement of target populations

127 Ruth Stephen: The Finnish Geriatric Intervention Study to prevent cognitive impairment and disability (FINGER): findings from the structural brain MRI sub-study

126 Timo Pekkala: Multimodal Prediction of Dementia and Brain Pathology


125 Kasper Katisko: Alterations of Immune System Function in Frontotemporal Lobar Degeneration – Emphasis on Comorbidities and Peripheral Inflammatory Markers


124 Emmi Reijula: Indicators of therapeutic misconception and willingness to participate in clinical drug trials : a survey among patients with epilepsy and Parkinson’s disease

123 Fanni Haapalinna: Alzheimer’s disease cerebrospinal fluid biomarkers in a cognitively healthy population and in patients with memory disorders: emphasis on co-morbidities and preanalytical factors.

122 Lili Cui: Safety and homing of intracarotidly delivered mesenchymal stem cells for treating ischemic stroke.


121 Emmi Bruun: Antiepileptic drug treatment in the elderly : choice of initial treatment, potential interactions and seizure outcome.

120 Anne-Mari Kantanen:  Intensive care treated refractory status epilepticus : incidence and outcome in Finland 2010-2012.

119 Teemu Paajanen: CERAD neuropsychological battery and structural magnetic resonance imaging in the detection of mild cognitive impairment and prodromal Alzheimer’s disease.

118 Kristiina Hongisto: Quality of life and neuropsychiatric symptoms in patients with Alzheimer´s disease – ALSOVA follow-up study.

117 Bushra Imtiaz: Hormone therapy and the risk of dementia, cognitive decline and Alzheimer’s disease.


116 Elina Siira:  The neuronal effects of Interleukin-18: Implications for Alzheimer’s disease.

115 Eino Solje: The spectrum of the phenotypes in the C9ORF72 expansion carriers. Insights at the interface between neurology and psychiatry.


114 Tuomas Rauramaa: Hippocampal lesions in aged populations: neuropathological and epidemiological studies.

113 Anna Junttila: Cerebrospinal fluid and plasma biomarkers in the differential diagnosis of neurodegenerative diseases.

112 Pekka Miettinen: Functional magnetic resonance imaging in Azheimer’s disease.

111 Bhimashankar Mitkari: Intra-arterial delivery of human bone marrow mesenchymal stem cells in rats with cerebral ischemia.

110 Ilona Hallikainen: Cognitive performance and progression of Alzheimer’s disease: measurement and intervention. The ALSOVA follow-up study.


109 Miguel Ángel Muñoz Ruiz: Disease State Index and neuroimaging in frontotemporal dementia, Alzheimer’s disease and mild cognitive impairment.

108 Miika Vuorinen: Cardiovascular risk factors and dementia-related structural brain changes on MRI.

107 Anu Lipsanen: Secondary neuropathology after experimental stoke with special emphasis on calcium, amyloid-β and inflammation.

106 Teemu Natunen: Genetic and functional studies of genes involved in Alzheimer’s disease pathogenesis.

105 Marjo Eskelinen: The effects of midlife diet on late-life cognition.


104 Leena Jutila: Surgical treatment of refractory temporal lobe epilepsy: Predictors of long-term outcome.

103 Minna Rusanen: Smoking, pulmonary and heart diseases and the risk of cognitive impairment and dementia: an epidemiological approach.


102 Valtteri Julkunen: Cortical thickness analysis in early diagnostics of Alzheimer’s disease.

101 Toni Seppälä: Blood and cerebrospinal fluid biomarkers of Alzheimer’s disease – application in the evaluation of progression and differential diagnosis.

100 Gabriela Spulber: Imaging the progression from Mild Cognitive Impairment to Alzheimer’s disease.


99 Timo Sarajärvi: Alzheimer’s disease-related genes and pathways. Special emphasis on seladin-1, δ-opioid receptor and BACE1.

98 Allan Seppänen: Collagen XVII in the human brain.

97 Jayashree Viswanathan: Genetic and functional characterisation of Alzheimer’s disease-associated risk genes.


96 Leena Aho: Amyloid-β deposition in the brains of subjects with cerebrovascular disease, diabetes, synucleinopathy and alcohol abuse: a human post mortem study.

95 Arto Immonen: Surgical treatment of refractory temporal lobe epilepsy : preoperative evaluation and seizure outcome.



94 Sari Rastas: Vascular risk factors in the very old with emphasis on mortality and cognition.

93 Alina Solomon: Cholesterol and late-life cognition. An epidemiological and clinical approach.

92 Anna Hicks: Intracerebral stem cell transplantation in experimental stroke models.


91 Anne Jauhiainen: Functional and structural magnetic resonance imaging studies in mild cognitive impairment and Alzheimer’s disease.


90 Saila Vepsäläinen: A molecular genetic study and expression-based analysis of risk factors of Alzheimer’s disease. Emphasis on amyloid beta degrading enzymes, IDE and NEP.

89 Heli Karhunen: Long-term studies of epileptogenesis after focal cerebral ischemia in rats.

88 Sanna-Kaisa Herukka: Usefulness of cerebrospinal fluid biomarkers in diagnosis of early Alzheimer’s disease.

87 Katriina Viinikainen: Epilepsy, female reproductive health and neurodevelopment of the offspring.

86 Jari Huuskonen: Microglial response to inflammatory stimuli-impact of protein acetylation and phosphorylation.


85 Corina Pennanen: Brain atrophy in Mild Cognitive Impairment: MRI volumetric and voxel-based method study.

84 Petri Kerokoski: Regulation of cyclin-dependent kinase-5 (Cdk5) with special emphasis on changes occurring during neuronal cell death.

83 Minna Korolainen: Proteomic analysis of post-translationally modified proteins in Alzheimer’s disease.

82 Taneli Heikkinen: Cognitive effects of estrogen in ovariectomized, aged and transgenic mice modeling Alzheimer’s disease.

81 Anne Koivisto: Genetic components of late-onset Alzheimer’s disease with special emphasis on ApoE, IL-6, CYP46, SERPINA3 and PPARγ.

80 Marina Boccardi: MRI studies in frontotemporal dementia.


79 Giedrius Kalesnykas: Cholinergic neurons of the rodent basal forebrain and their content of estrogen receptor alpha.

78 Jouni Ihalainen: Regulation of dopamine release in the forebrain by alpha2 adrenoceptors and NMDA glutamate receptors.

77 Susan Iivonen: Genetic and expressional studies of Alzheimer’s disease candidate genes. Emphasis on CYP19, seladin-1 and HSPG2 genes.

76 Iain Wilson: Hippocampal place cells as a window into cognitive aging.

75 Laura Parkkinen: Impact of alfa-synuclein pathology on aging.

74 Sinikka Peurala: Rehabilitation of gait in chronic stroke patients.

73 Dimitrije Jakovljevic: The roles of chronobiological and socioeconomic factors in the occurrence of cerebrovascular diseases.

72 Chuan-sheng Zhao: Psychotrophic medication and functional recovery following cortical stroke in aged rats.


71 Maija Pihlajamäki: Functional MRI studies on human declarative memory.

70 Erkki Kuusisto: Role of the p62 protein in the formation of neuropathological cytoplasmic inclusions.


69 Jaana Autere: Genetics of Parkinson’s disease in the finnish population.

68 Johanna Kuhmonen: Neuroprotection in experimental acute cerebral ischaemia.

67 Juhana Aura: Interaction of muscarinic acetylcholine and N-methyl-D-aspartate-type glutamate receptors in the regulation of spatial learning and memory.

66 Jun Wang: The role of Ab-peptide on spatial memory, EEG, auditory evoked potentials and nicotinic cholinergic receptors in A/P transgenic mice.

65 Li Liu: Cholinergic neurotransmission, amyloid-b peptide and the pathogenesis of Alzheimer’s disease. A study in the APP and PS1 double transgenic mouse model.


64 Marja Äikiä: Verbal memory in newly diagnosed partial epilepsy. A neuropsychological study.

63 Margit Overmyer: Gliosis in relation to Alzheimer’s hallmark lesions in aging and Alzheimer’s disease. A postmortem immunohistochemical study.

62 Miia Kivipelto: Vascular risk factors in Alzheimer’s disease and mild cognitive impairment: a longitudinal, population-based study.

61 Pauliina Korhonen: Gene regulation in neuronal degeneration – role of mSin3 and YY1 factors.

60 Inga Kadish: Plasticity in the entorhinal-hippocampal pathway. Influences of gene mutations and hormones.


59 Maaria Ikonen: Apoptosis-associated changes in neuronal gene expression. With special emphasis on the insulin-like growth factor system.

58 Kirsi Puurunen: The effects of pharmacotherapy and training on functional recovery after global and focal cerebral ischemia in rats.

57 Tero Tapiola: Biological markers for Alzheimer’s disease. With special emphasis on cerebrospinal fluid b-amyloid and tau.

56 Zinayida Bezvenyuk: Multiple pathways of DNA disintegration during neuronal apoptosis.

55 Tuuli Salmenperä: Damage in the hippocampus, amygdala, entorhinal and perirhinal cortex of adults with partial epilepsy.

54 Sami Ikonen: The role of the septohippocampal cholinergic system in cognitive functions.


53 Mikko Hiltunen: A molecular genetic study of factors involved in Alzheimer’s disease.

52 Kauko Pitkänen: Stroke rehabilitation in the elderly. A controlled study of the effectiveness and costs of a multidimensional intervention.

51 Jukka Puoliväli: An experimental study on the cholinergic modulation of cortical arousal and cognitive functions. With special emphasis on apolipoprotein E.


50 Mia Mikkonen: The human entorhinal cortex: anatomic organization and its alteration in Alzheimer’s disease and temporal lobe epilepsy.

49 Tarja Puumala: Monoamines in the modulation of attention and response inhibition: development of a new animal model of attention deficit and impulsivity.

48 Raimo Pussinen: An experimental study on the role of alpha1-adrenoceptors and putrescine in the modulation of hippocampal plasticity and memory encoding – Interactions with NMDA receptors.


47 Kirsi Juottonen: MRI volumes of the entorhinal, perirhinal and temporopolar cortices in normal aging and Alzheimer’s disease.

46 Matti Vanhanen: Cognitive function in glucose intolerance in the elderly: the role of hyperinsulinemia.

45 Merja Hallikainen: Age-associated memory impairment, and apolipoprotein E. A population-based clinical, neuropsychological, neurophysiological, and neuroimaging study.

44 Seppo Helisalmi: Molecular genetics of Alzheimer’s disease. With special emphasis on presenilin, amyloid beta precursor protein and apolipoprotein E genes.


43 Sirja Ruotsalainen: Serotonergic system and its interactions with cholinergic receptor mediated mechanisms in the modulation of working memory. An experimental study.

42 Tiina Kotti: Excitotoxicity-induced neuropathological changes in the rodent hippocampus. Possible functional consequences and drug treatments.

41 Heikki Sorvari: Neurons containing calcium-binding proteins in the human amygdaloid complex.

40 Vesa Savander: Organization of intrinsic connections in the rat amygdaloid complex. With special emphasis on the lateral, basal and accessory basal nuclei.


39 Tuomo Hänninen: Age-associated memory impairment. A neuropsychological and epidemiological study.

38 Maarit Lehtovirta: Familial Alzheimer’s disease. A clinical and molecular genetic study.

37 Mikko Laakso: MRI of hippocampus in incipient Alzheimer’s disease.

36 Olli Kosunen: A neuropathologic study on Alzheimer’s disease with a special emphasis on diagnostic accuracy.


35 Mervi Pitkänen: The role and pharmacological modulation of the NMDA receptor/channel on hippocampal synaptic transmission and behavior.

34 Arja Tuunainen: Evaluation of epileptic patients for temporal lobe surgery and postoperative follow-up. An electrophysiological study with neuropsychological, psychiatric and clinical correlates.


33 Keijo Koivisto: Population-based dementia screening program in the city of Kuopio, Eastern Finland: Evaluation of screening methods, prevalence of dementia and dementia subtypes.

32 Minna Riekkinen: The interaction between cholinergic and serotononergic systems in the modulation of spatial navigation and passive avoidance behavior.

31 Outi Heinonen: Neuropathological and peripheral markers of Alzheimer’s disease with special emphasis on b-amyloid accumulation.

30 Päivi Hartikainen: Normal ageing. A neurochemical, neurophysiological and neuropsychological study with special reference to Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis.


29 Hannele Lahtinen: Hippocampus in experimental models of temporal lobe epilepsy. Amino acid mediated neurotransmission and nerve cell injury following the transsection of fimbria-fornix and electrical stimulation of perforant pathway in rat.

28 Riitta Miettinen: Inhibitory circuits and subcortical innervation of the rat hippocampus: Implications for normal function and pathophysiological processes.


27 Kari Alhainen: Anticholinesterase drug, tacrine (THA), in Alzheimer’s disease. Discrimination of responders and nonresponders.

26 Pekka Jäkälä: Modulation of attention and working memory by noradrenergic, serotonergic and cholinergic systems. An experimental neuropsychopharmacological study.

25 Maria Mazurkiewicz: The effects of enhanced GABAergic transmission on cognitive functions: An experimental study.

24 Reetta Kälviäinen: Newly diagnosed epileptic seizure disorder in adults. A prospective follow-up study on 100 patients.

23 Aimo Rissanen: Cerebrovascular disease in Jyväskylä region, Central Finland.

22 Antti Valjakka: The subcortical afferentation of the hippocampus and noradrenergic lesions as experimental models of dementia.


21 Aarne Ylinen: Hippocampal reactions and their pharmacotherapy in experimental epilepsy.

20 Kari Murros: Stress reactions of brain infarction. A prospective study on 105 patients with acute ischemic brain infarction of internal carotid artery territory.


19 Ulla Lepola: Panic disorder. A clinical, neurochemical, neuropsychological and neuroradiological study.

18 Toivo Halonen: Neurotransmitter amino acids in epileptic convulsions and during vigabatrin treatment.

17 Paavo Riekkinen Jr.: Animal models of age-related degeneration of subcortical regulatory system. With special reference to cholinergic, noradrenergic and serotonergic systems.

16 –

15 Eeva-Liisa Helkala: Memory in patients with Alzheimer’s disease and demented patients with Parkinson’s disease.


14 Asla Pitkänen: Somatostatin in experimental and human epilepsy.

13 Hannu Koponen: Delirium in the elderly. A clinical, neurochemical, neurophysiological and neuroradiological study.

12 Jouni Sirviö: The cholinergic system in ageing and dementia. With special reference to acetylcholinesterase.


11 Jukka Jolkkonen: Vasopressin in the central nervous system. A study based on cerebrospinal fluid measurements.

10 Tapani Keränen: Epilepsy in adults. An epidemiological study in Eastern Finland.

9 Kari Reinikainen: Neurotransmitters in Alzheimer’s disease.


8 Esa Mervaala: Evoked potential in human epilepsy. A neurophysiological study.

7 Asla Pitkänen: Somatostatin in epilepsy. An experimental and clinical study.


6 Juhani Sivenius: Studies on rehabilitation, epidemiology and clinical features of stroke in East Central Finland.

5 Markku Saksa: The autonomic nervous system in experimental allergic neuritis. A functional, morphological and biochemical study.

4 Rolf Danner: Adverse effects of anticonvulsive treatment on peripheral nerve conduction and posterior dominant EEG rhythm.


3 Hilkka Soininen: Senile dementia. A clinical, neurochemical and etiological study.

2 Eeva Leino: Clinical and biochemical studies on progressive myoclonus epilepsy.


1 Juhani Partanen: Time-locked phenomena of human motor unit potentials. An electromyographic study of satellites and doubles.